1 | INTRODUCTION

This guideline serves as an update to and replacement of the 2018 ISPAD consensus guideline on stages of type 1 diabetes (T1D). Herein, we provide an evidence-based summary of recommendations for screening children for T1D risk and discuss potential opportunities for clinical trials designed to delay progression to Stage 3 T1D and preserve beta cell function in those with Stage 3 disease. We again use the American Diabetes Association’s metrics for grading evidence from A through E. We acknowledge that priorities may differ in low-income countries that may not be able to offer screening.

2 | WHAT IS NEW OR DIFFERENT

- Stages 1, 2, 3, and 4 T1D are being used in clinical, research, and regulatory settings.
- General population screening programs to determine T1D risk are expanding.
- Collaborative T1D networks testing interventions seeking to delay the disease process at all stages of disease are growing.
- Tools to predict T1D and response to interventions are improving.
- Anti-CD3 monoclonal antibody (teplizumab) is being evaluated by the U.S. Food and Drug Administration (FDA) for use to delay progression from Stage 2 to Stage 3 T1D.
EXECUTIVE SUMMARY: RECOMMENDATIONS AND PRINCIPLES

- Individuals with a first-degree relative with T1D have ~15-fold increased relative risk of developing T1D (A).
- Individuals with two or more islet autoantibodies and normoglycemia have stage 1 T1D (A).
- The vast majority (80% - 90%) of children with multiple islet autoantibodies progress to Stage 3 within 15 years, compared with ~15% who have a single islet autoantibody. Nearly 100% of children with multiple autoantibodies will ultimately progress to Stage 3 T1D (A).
- Progression rates are similar between individuals with a family history of T1D and those from the general population (A).
- Targeted screening and monitoring identifies individuals with Stage 1, Stage 2, and pre-symptomatic Stage 3 diabetes, reduces the incidence of diabetic ketoacidosis (DKA), reduces rates of hospitalization, and directs individuals toward studies seeking to delay or prevent ongoing beta cell loss (A).
- General population screening programs using combinations of genetic and autoantibody testing can identify high-risk children (A).
- Both general population and targeted screening should be coupled with education and monitoring programs for those identified with autoantibodies (B).
- Autoantibody screening at ages 2 and 6 years may provide for optimal sensitivity and positive predictive value in public health settings (B).
- When immunotherapies capable of delaying progression are approved by regulatory bodies and economic issues related to screening are optimized, general pediatric population screening for islet autoantibodies is expected to be implemented in many regions (E).
- Individuals who screen positive for genetic or immunological markers of T1D, whether identified through research or community-based screening programs, should have access to information regarding available prevention studies (E).
- An oral glucose tolerance test (OGTT) is recommended to stage disease in individuals with two or more islet autoantibodies prior to recruitment into prevention trials, and can be used to counsel individuals on risk of progression (E).
- Self-monitoring of blood glucose (SMBG), HbA1c, and continuous glucose monitoring (CGM) can be utilized to inform disease progression and may be considered where OGTT is impractical or not available (E).
- SMBG and CGM are simple measures that can be taught and provided to families allowing real-time information to prevent DKA (E).
- As screening programs expand, individuals with early and late Stage 2 and asymptomatic or symptomatic Stage 3 diabetes will be more commonly identified and additional sub-classifications or stages are likely to be adopted (e.g., Stage 3a [asymptomatic] or Stage 3b [symptomatic]) (E).

3.1 Stages of T1D

T1D is characterized by four stages as shown in Figure 1.

- **Stage 1**: Multiple islet autoantibodies, normal blood glucose, pre-symptomatic.
- **Stage 2**: Multiple islet autoantibodies, abnormal glucose tolerance, usually pre-symptomatic.
- **Stage 3**: Blood glucose above ADA diagnostic thresholds.
- **Stage 4**: Established T1D.

A proportion of individuals who have increased genetic risk of T1D progress at variable rates to immune activation and the development of islet autoimmunity. The development of 2 or more islet autoantibodies (Stage 1), is typically followed by a period of pre-clinical dysglycemia (Stage 2), though this stage may not be detected in all individuals if progression is rapid. Individuals who develop Stage 3 T1D may be asymptomatic or symptomatic. Established T1D is described as Stage 4 T1D.

3.2 Risk of T1D

Individuals with a first degree relative with T1D have an ~15-fold increased relative lifetime risk of T1D compared to the general population and the prevalence of T1D by age 20 years is ~5% compared to ~0.3%, respectively. However ~85% of individuals with a new diagnosis do not have a family history of T1D.

The various stages inform the risk of progression; children with a single islet autoantibody have a ~15% risk of reaching Stage 3 T1D within 10 years. In contrast, children at Stage 1 have a 44% 5-year risk and 80% 15-year risk of developing Stage 3 T1D, and children at Stage 2 have a 75% 5-year risk and a 100% lifetime risk of developing Stage 3 T1D.

3.2.1 Genetic risk

More than 70 genetic T1D variants have been identified through genome-wide association studies. The highest-risk HLA haplotypes are DRB1*03:01-DQA1*05:01-DQB1*02:01 (also expressed as DR3-DQ2) and DRB1*04-DQA1*03:01-DQB1*03:02 (also expressed as DR4-DQ8). In the general population, children with the HLA DR3-DQ2/DR4-DQ8 genotype have ~5% risk for islet autoimmunity and T1D. First-degree relatives carrying HLA DR3-DQ2/DR4-DQ8 have a further increase in risk that reaches ~20%. Additional risk provided by non-HLA risk genes is roughly equivalent to that provided by HLA DR-DQ alone. The highest non-HLA genetic contribution arises from the INS and PTPN22 genes. These, and other risk regions, are included in polygenic risk scores that combine HLA and non-HLA genes to substantially improve risk estimates for islet autoimmunity and T1D, particularly in the general population. Notably, the risk of developing islet autoimmunity...
declines exponentially with age as does the influence of genetic factors, although there is a paucity of data in adults.\textsuperscript{21-23} Furthermore, once a child develops multiple islet autoantibodies, HLA and polygenic risk scores have only limited further predictive value for stratifying the rate of progression to diabetes.\textsuperscript{3,24-26}

3.2.2 | Environmental exposures

The increasing incidence of T1D globally coupled with a reduction in the proportion of individuals with the highest risk HLA haplotypes developing T1D, highlights the significant contribution environmental exposures play in the pathogenesis of T1D.\textsuperscript{27} Different environmental exposures likely interact with multiple risk genes to drive the development of islet autoimmunity and the progression to Stage 3 T1D. Putative exposures are likely to vary across individuals and in combination with different gene—environment and environment—environment interactions. The impact of nutrition, growth, and infections and their interactions with the “omic” biological systems have been investigated in epidemiological studies and in at-risk cohorts, from birth, and more recently, from pregnancy.\textsuperscript{28} The onset of islet autoimmunity from infancy implicates very early life exposures in some children.\textsuperscript{28}

3.3 | Screening for pre-symptomatic T1D

Screening for risk of T1D is gaining international momentum. While the majority of screening programs remain within the context of research trials, implementation science programs in Europe, the United States, and Australia are actively demonstrating feasibility and acceptability.\textsuperscript{29} In time, screening is likely to be embedded in local, regional, and national health systems as the standard of care. That said, optimal models for screening and staging for T1D remain unclear and will ultimately depend on several factors, including the screening objective, the structure of the local health care system, and available resources.

3.3.1 | Goals of screening

The long-term vision for T1D screening programs is to identify individuals at risk of, or with early-stage, T1D to offer them interventions to delay and, ultimately, prevent the condition. However, there are other important and currently achievable clinical benefits that drive current recommendations for screening, including to:

1. Prevent DKA and its associated short- and long-term morbidity and mortality.
2. Prepare children and families for a smoother transition to insulin therapy.
3. Advance preventative therapies through clinical trial recruitment.

Screening programs significantly reduce DKA rates, usually to less than 5%, and reduce hospitalization when coupled with long-term monitoring.\textsuperscript{3,30-33} The rates of DKA at diagnosis range from 15% to 70% in Europe and North America and as high as 80% in under-resourced countries.\textsuperscript{34-39} DKA prevention at diagnosis has potential lifelong benefits, including avoidance of acute morbidity (cerebral oedema, shock), neurocognitive impairment, and mortality.\textsuperscript{40,41} There are also non-causal associations between DKA at onset and future risk of DKA,\textsuperscript{38,42} severe hypoglycemia,\textsuperscript{42} and long-
term hyperglycemia which increases the risk of serious future diabetes-related complications. Furthermore, parental anxiety at diagnosis is approximately halved for children in screening programs compared to the general community. The additional time provided for counseling, preparation for insulin therapy and education, delivered across time in the community or outpatient setting, may help reduce parental anxiety and smooth the transition to symptomatic T1D and insulin requirement.

Screening also identifies children suitable for recruitment into clinical prevention trials, which include screening platforms such as T1D TrialNet, Type1Screen, AutoImmunity Screening for Kids (ASK), INNODIA and GPPAD (Global Platform for the Prevention of Diabetes).

3.3.2 | Target population for screening

Given the current inability to intervene effectively in the T1D disease process, international debate continues about whether screening should be population-wide or limited to first-degree family members. Notably, current evidence suggests that the rate of disease progression, once Stage 1 diabetes is confirmed, is not significantly different between individuals with a family member compared to the general population. Routine screening for family members as part of clinical care has been proposed as an intermediate step toward general population screening. However, as DKA rates are lower in individuals with a first-degree relative of T1D compared to those without and the vast majority of individuals (at least 85%) who develop T1D do not have a family history of the disease, meaningful DKA prevention will ultimately require population-wide screening.

3.3.3 | Screening modalities

There are currently two primary strategies used for T1D screening.

2. Genetic risk-stratified islet autoantibody screening.

Islet autoantibody screening aims to identify individuals in the target population with pre-symptomatic, Stage 1 or Stage 2 T1D. Advancements in islet autoantibody assays are enabling ultra-low blood volumes, including testing using capillary samples and dried bloodspots, which facilitate minimal invasive collection at home or in community settings. Several groups have tried to determine optimal ages for performing autoantibody screening; modeled data from international cohort studies suggest the sensitivity of one-off autoantibody screening between the ages of 3–5 years is ~35% and can be improved to ~50% with repeated population screening at both 2–3 years and 5–7 years. Notably, sampling from 2 years of age does not capture all children who will develop T1D and misses the small, but important, subset of infants and toddlers who rapidly develop T1D in the first 2 years of life and who have the highest rates of DKA with the greatest risk for associated morbidities. Additional studies and analyses are needed to balance sensitivity, specificity, public health priorities, cost, and local resources when developing specific screening programs.

Genetic risk factors can be used to identify the subset of children with an increased risk of T1D who would benefit most from islet autoantibody screening. Such an approach has also been used in GPPAD to efficiently identify children with the highest risk of developing T1D for prevention trials (e.g., in the Primary Oral Insulin Trial).

Genetic risk can be broadly inferred through family history of T1D, as in T1D TrialNet, or assessed using a polygenic risk score in the general population. Some international programs, including GPPAD, evaluate polygenic risk scores from dried bloodspots collected as part of the existing Newborn Screening Program, thereby leveraging existing infrastructure and reducing the need for an additional screening intervention. As polygenic risk scores are a continuous scale, the threshold defining “at-risk” can be altered to suit the screening purpose. For example, lowering the threshold from the top 1% to the top 10% of infants by risk, reduces their risk of T1D from 10% to 2.4% but increases the number of future cases captured from ~30% to ~80%. A high threshold may be considered more effective if the primary goal is to enroll children into prevention trials, while lower thresholds may be better suited to efforts prioritizing DKA prevention, because they capture a greater proportion of future cases. Currently all polygenic risk scores for T1D have been developed using largely Caucasian datasets. While the incidence of T1D is higher in Caucasian individuals, a polygenic risk score that is either validated in or developed specifically for diverse ethnicities will be required for population-wide routine screening.

3.3.4 | Follow-up in high genetic risk children

The optimal frequency of islet autoantibody testing in genetically high-risk individuals remains unclear. Clinical trials have utilized varying frequencies of antibody screening in high genetic risk children. Some efforts have screened every 3 months through 2 years of life (TEDDY), while some obtain annual antibodies, and others have proposed at least once between 1 and 5 years of age. More frequent monitoring may be beneficial in infants and toddlers, given their rapid progression to Stage 3 T1D and increased risk of severe DKA. Nevertheless, the economic and psychological impacts of repeated screening must always be considered.

3.3.5 | Glycemic surveillance in individuals with islet autoimmunity

Once a young person has multiple islet autoantibodies, they should be offered glycemic staging and ongoing monitoring to identify disease...
progression. The intensity of those efforts should depend on the goals of the family or any related research study and will be influenced by resource availability. Those seeking staging for potential inclusion in a prevention trial generally require an OGTT (see next section), whereas, less intensive methods may be suitable in children who are identified or monitored outside of a research setting. Here, the goal should be to counsel families about future risk of Stage 3 T1D and the options for glycemic monitoring, how to identify signs and symptoms of hyperglycemia, preparation for a smooth transition to insulin therapy and preventing DKA.

3.3.6 | Oral glucose tolerance test

In the setting of multiple autoantibodies, the standard 2-h oral glucose tolerance test (OGTT) following 1.75 g/kg (75 g maximum) oral glucose administration remains the gold standard test for disease staging (see “Stages of diabetes” section above). In addition, glucose values of ≥11.1 mmol/L (≥200 mg/dl) obtained at 30, 60, and 90 min after glucose administration have been used in the research setting to inform the risk of progression. Furthermore, mid OGTT glucose values ≥11.1 mmol/L (≥200 mg/dl) can be used to formally diagnose Stage 3 T1D in the setting of an elevated HbA1c or fasting glucose.

Categories for fasting plasma glucose (FPG) are defined as follows:

- FPG <5.6 mmol/L (<100 mg/dl) = Stage 1 (normal fasting glucose)
- FPG 5.6–6.9 mmol/L (100–125 mg/dl) = Stage 2 (impaired fasting glucose)
- FPG ≥7.0 mmol/L (≥126 mg/dl) = Stage 3 T1D

Categories for 2-h plasma glucose following OGTT are defined as follows:

- Two-hour glucose 7.8–11.1 mmol/L (140–199 mg/dl) = Stage 2 (impaired glucose tolerance).
- Two-hour glucose ≥11.1 mmol/L (≥200 mg/dl) = Stage 3 T1D.

In the presence of multiple islet autoantibodies, the addition of other metrics such as age, sex, C-peptide, insulinoma-associated-2 autoantibody (IA-2A), HbA1c, and BMI allows calculation of scores which provide information on the risk of progression to stage 3 T1D. These include the 5-timepoint Diabetes Prevention Trial-Type 1 Risk Score (DPTRS), the two-timepoint DPTRS60, and Index60 and the single timepoint M120. These scores have similar levels of performance and are superior to using impaired glucose tolerance (IGT) alone. While the majority of these scores have been developed using data from first-degree relatives being monitored in longitudinal natural history studies, the recently published progression likelihood score from the Fr1Da program showed a 48% year progression rate from stage 2 T1D to stage 3 T1D in children identified from the general population.

While the OGTT is recommended as the gold standard for staging children, especially those seeking entry into intervention trials, it is not always feasible or acceptable. Alternative approaches are discussed next (Table 1).

### 3.3.7 | Glycosylated hemoglobin (HbA1c)

HbA1c is a specific but insensitive indicator of early onset diabetes. The risk of progression is increased in the context of: (1) 10% rise in HbA1c in the non-diabetic range on two consecutive occasions collected 3–12 months apart (median time to “clinical diagnosis”: 1.1 years, hazard ratio 5.7); (2) two HbA1c values >41 mmol/mol (5.9%) (median time to “clinical diagnosis”: 0.9 year, hazard ratio 11.9); and (3) HbA1c >39 mmol/mol (5.7%), which is an independent predictor for progression. Caution is needed in relying on HbA1c in young children who may progress rapidly, and may be missed before a rise in...
HbA1c can be observed or in the setting of an undiagnosed hemoglobinopathy or other conditions that affect erythrocyte turnover.  

3.3.8 | Continuous glucose monitoring

Normative data taken from children, adolescents, and adults who are islet autoantibody-negative demonstrate a narrow variability in glucose using continuous glucose monitoring (CGM).  

CGM provides real-time data and may be useful in identifying children with increased glucose variability in addition to elevated blood glucose levels.  

In the largest pediatric study to date assessing CGM as a tool to predict progression, a cut-off of 10% time spent at >7.8 mmol/L (>140 mg/dl) had an 80% risk of progression to Stage 3 T1D over 1 year (91% specificity, 97% NPV, 88% sensitivity, 67% PPV).  

However, further validation is needed, especially in very young children, to provide better evidence of when and how to begin insulin therapy.

3.3.9 | Random venous glucose and self-monitoring fingerstick blood glucose

In the Finnish DIPP study, the median time to diagnosis after a random plasma glucose ≥ 7.8 mmol/L (140 mg/dl), was 1.0 year in children at Stage 1.  

Random plasma glucose is a simple and low-cost measurement with comparable predictive characteristics to that of OGTT-derived 2-h glucose value, but with relatively poor sensitivity of 21% (95% CI 16%, 27%) and a specificity of 94% (95% CI 91%, 96%).  

Surprisingly little evidence exists for the accuracy of capillary self-monitoring fingerstick blood glucose (SMBG) in pre-symptomatic T1D in childhood, but it is a simple method that could be used in isolation or with other metrics. Adult data suggests that capillary glucose is a reliable comparator to venous glucose concentrations (85% to 90% accuracy for diabetes or IGT) during the OGTT.  

3.3.10 | Recommendations for staging and monitoring

An OGTT is recommended as the gold standard for staging children for recruitment into clinical trials. When OGTT is not feasible, alternative approaches might include a 6–12 monthly HbA1c and 2-h postprandial or random glucose, dependent on risk stratification. More frequent monitoring may be offered to children at high risk of progression (e.g., those who seroconvert before age 2, with high IA-2A, or ≥3 islet autoantibodies).  

If available, CGM could be added if dysglycemia is identified. HbA1c and CGM data can provide information on those progressing to insulin requirement within ~12 months, providing an opportunity to counsel individuals/carers and to commence education as an outpatient. SMBG measurements can provide families with real-time data to allow early detection of hyperglycemia and prevention of DKA.

3.4 | Psychological burden

A major concern with screening is engendering anxiety and imposing disease monitoring burden prior to insulin requirement, especially given there is currently no approved preventive therapy. The majority of children screened as being at increased genetic risk will never develop T1D and, and for those with early-stage T1D, the latency period may last years.  

“Positive” genetic and islet autoantibody screening results are associated with increased parental stress, particularly in mothers; however, this declines rapidly within 3–12 months. Furthermore, research programs that have monitored children both at high genetic risk and those identified through islet autoantibody surveillance programs report reduced stress overall in children and their parents at the time when insulin therapy is needed compared to community controls. The Fr1da study showed that initial stress associated with multiple autoantibodies was only ~50% of that seen in families where children were diagnosed outside of the screening program. These findings are likely explained by the high rates of depression and parenting stress when T1D is diagnosed and requires emergency insulin therapy. The psychological burden in children and parents who continue to undergo glycemic monitoring without developing Stage 3 T1D for some years remains uncertain.

3.5 | Cost-effectiveness

A major consideration is the total cost and the incremental cost-effectiveness for screening, education, and monitoring programs. Cost-effectiveness analyses in the United States for islet autoantibody-only screening suggests that screening can be cost-effective with a 20% reduction in DKA at diagnosis and a 0.1% (1.1 mmol/mol) reduction in HbA1c during a lifetime. Further economic modeling is required, including assessment of different screening and monitoring models of care as well as in individual countries due to differing health systems, burden of T1D, and costs of treatment locally. In the future, approval of preventive therapies will incur additional treatment costs but also likely result in substantial healthcare cost-savings and improved health benefits, further improving the incremental cost-effectiveness ratio.

In some lower resource countries, islet autoimmunity and genetic risk may be more heterogeneous, adding further complexity to screening. Lower-resource countries often have higher rates of DKA and islet autoantibody-associated mortality, however, the lower T1D incidences in most of these countries may make screening efforts less cost-effective. Priorities in such countries continue to be correct etiological diagnosis as well as access to and improvements in clinical care for Stage 3 T1D.

3.6 | Efforts to slow disease progression

3.6.1 | Primary and secondary prevention efforts

Efforts to prevent the development of autoimmunity have historically been referred to as primary prevention, while efforts to delay...
<table>
<thead>
<tr>
<th>Trial</th>
<th>Route</th>
<th>Intervention</th>
<th>Population</th>
<th>Primary outcome</th>
<th>Outcome achieved</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Primary prevention</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>BABYDIET</td>
<td>PO</td>
<td>Late gluten exposure</td>
<td>Genetically at-risk infants</td>
<td>Islet autoimmunity</td>
<td>Unsuccessful</td>
</tr>
<tr>
<td>FINDIA</td>
<td>PO</td>
<td>Bovine insulin-free formula</td>
<td>Genetically at-risk infants</td>
<td>Islet autoimmunity</td>
<td>Successful</td>
</tr>
<tr>
<td>TRIGR</td>
<td>PO</td>
<td>Hydrolyzed casein formula</td>
<td>Relatives, genetically at-risk infants</td>
<td>Stage 3</td>
<td>Unsuccessful</td>
</tr>
<tr>
<td>Pre-POInT</td>
<td>PO</td>
<td>Insulin</td>
<td>Relative, HLA risk, AAb neg, 3–7 y</td>
<td>AAb and T cell responses</td>
<td>Successful</td>
</tr>
<tr>
<td>Pre-POInT-early</td>
<td>PO</td>
<td>Insulin</td>
<td>Relative, HLA risk, AAb neg, 6 m–2 y</td>
<td>AAb and T cell responses</td>
<td>Unsuccessful</td>
</tr>
<tr>
<td>POInT</td>
<td>PO</td>
<td>Insulin</td>
<td>Relative, HLA risk, AAb neg, 4–7 m</td>
<td>Islet autoimmunity</td>
<td>Ongoing</td>
</tr>
<tr>
<td>SINT1A</td>
<td>PO</td>
<td><em>B. Infantis</em> probiotic</td>
<td>Relative, genetic risk, 7 days–6 weeks</td>
<td>Islet autoimmunity</td>
<td>Ongoing</td>
</tr>
<tr>
<td><strong>Secondary prevention</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CORD IV</td>
<td>Autologous Cord Blood</td>
<td>Relative or Gen Pop, Age &lt; 15, ≥2 Ab</td>
<td>Stage 3</td>
<td>Ongoing</td>
<td></td>
</tr>
<tr>
<td>ENDIT PO</td>
<td>PO</td>
<td>Nicotinamide</td>
<td>Relative, ICA+, normal OGTT</td>
<td>Stage 3</td>
<td>Unsuccessful</td>
</tr>
<tr>
<td>DPT-1 IV/SC</td>
<td>Insulin</td>
<td>Relative, ICA+, IAΑ+, FPIR below threshold, 3–45 y</td>
<td>Stage 3</td>
<td>Unsuccessful</td>
<td></td>
</tr>
<tr>
<td>DPT-1 PO</td>
<td>Insulin</td>
<td>Relative, ICA+, IAΑ+, FPIR above threshold, 3–45 y</td>
<td>Stage 3</td>
<td>Unsuccessful</td>
<td></td>
</tr>
<tr>
<td>DIPP IN</td>
<td>Insulin</td>
<td>HLA risk, ≥2 AAb + 1, 1–15 y</td>
<td>Stage 3</td>
<td>Unsuccessful</td>
<td></td>
</tr>
<tr>
<td>INIT-I IN</td>
<td>Insulin</td>
<td>Relative, ≥1 Ab, normal FPIR, 4–32 y</td>
<td>FPIR change</td>
<td>Unsuccessful</td>
<td></td>
</tr>
<tr>
<td>INIT-II IN</td>
<td>Insulin</td>
<td>Relative, Stage 1, FPIR above threshold, 4–30y</td>
<td>Stage 3</td>
<td>Unsuccessful</td>
<td></td>
</tr>
<tr>
<td>Belgian registry SC</td>
<td>Insulin</td>
<td>Relative, IA−2Α+, 5–40 y</td>
<td>Stage 3</td>
<td>Unsuccessful</td>
<td></td>
</tr>
<tr>
<td>EPPSCIT SC</td>
<td>Insulin</td>
<td>Relative, ≥2 AAb, 7–14 y</td>
<td>Stage 3</td>
<td>Unsuccessful</td>
<td></td>
</tr>
<tr>
<td>TN-07 PO</td>
<td>Insulin</td>
<td>Relative, Stage 1 (IAΑ+ required), 3–45 y</td>
<td>Stage 3</td>
<td>Unsuccessful</td>
<td></td>
</tr>
<tr>
<td>Fr1da PO</td>
<td>Insulin</td>
<td>Stage 1, 2–12 y</td>
<td>Immune responders then Stage 2/3</td>
<td>Ongoing</td>
<td></td>
</tr>
<tr>
<td>DiAPREV-IT</td>
<td>SC</td>
<td>GAD</td>
<td>Stage 1 (GADA+ required), 4–17 y</td>
<td>Stage 3</td>
<td>Unsuccessful</td>
</tr>
<tr>
<td>TN-10 IV</td>
<td>Teplizumab</td>
<td>Stage 2, 8–45 y</td>
<td>Stage 3</td>
<td>Successful</td>
<td></td>
</tr>
<tr>
<td>TN-18 IV</td>
<td>Abatacept</td>
<td>Stage 1, 6–45 y</td>
<td>Stage 2</td>
<td>Ongoing</td>
<td></td>
</tr>
<tr>
<td>TN-22 PO</td>
<td>Hydroxy-chloroquine</td>
<td>Stage 1, 3–45 y</td>
<td>Stage 2 or 3</td>
<td>Ongoing</td>
<td></td>
</tr>
<tr>
<td><strong>Intervention</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>TN-05 IV</td>
<td>Rituximab</td>
<td>Stage 3, new onset, 8–40 y</td>
<td>AUC C-peptide</td>
<td>Successful</td>
<td></td>
</tr>
<tr>
<td>AbATE IV</td>
<td>Teplizumab</td>
<td>Stage 3, new onset, 8–30 y</td>
<td>AUC C-peptide</td>
<td>Successful</td>
<td></td>
</tr>
<tr>
<td>Protégeé IV</td>
<td>Teplizumab</td>
<td>Stage 3, new onset, 8–35 y</td>
<td>Insulin dose + HbA1c</td>
<td>Unsuccessful</td>
<td></td>
</tr>
<tr>
<td>T1DAL IM</td>
<td>Alefacept</td>
<td>Stage 3, new onset, 12–35 y</td>
<td>AUC C-peptide</td>
<td>Unsuccessful</td>
<td></td>
</tr>
<tr>
<td>EXTEND IV</td>
<td>Tocilizumab</td>
<td>Stage 3, new onset, 6–17 y</td>
<td>AUC C-peptide</td>
<td>Unsuccessful</td>
<td></td>
</tr>
<tr>
<td>T-Rex IV</td>
<td>Autologous Tregs</td>
<td>Stage 3, new onset, 8–17 y</td>
<td>AUC C-peptide</td>
<td>Unsuccessful</td>
<td></td>
</tr>
<tr>
<td>TN-09 IV</td>
<td>Abatacept</td>
<td>Stage 3, new onset, 6–45 y</td>
<td>AUC C-peptide</td>
<td>Successful</td>
<td></td>
</tr>
<tr>
<td>START IV</td>
<td>High-dose ATG</td>
<td>Stage 3, new onset, 12–35 y</td>
<td>AUC C-peptide</td>
<td>Unsuccessful</td>
<td></td>
</tr>
<tr>
<td>TN-19 IV</td>
<td>Low-dose ATG</td>
<td>Stage 3, new onset, 12–45 y</td>
<td>AUC C-peptide</td>
<td>Successful</td>
<td></td>
</tr>
<tr>
<td>T1GER SC</td>
<td>Golimumab</td>
<td>Stage 3, new onset, 6–21 y</td>
<td>AUC C-peptide</td>
<td>Successful</td>
<td></td>
</tr>
<tr>
<td>TN-14 SC</td>
<td>Canakinumab</td>
<td>Stage 3, new onset, 6–36 y</td>
<td>AUC C-peptide</td>
<td>Unsuccessful</td>
<td></td>
</tr>
<tr>
<td>PROTECT IV</td>
<td>Teplizumab</td>
<td>Stage 3, new onset, 8–17 y</td>
<td>AUC C-peptide</td>
<td>Successful</td>
<td></td>
</tr>
</tbody>
</table>

(Continues)
progression from Stage 1 or Stage 2 to Stage 3 diabetes are referred to as secondary prevention (Table 2). While a number of proposed therapies have been studied, teplizumab, a monoclonal antibody targeting the T cell surface marker CD3, is the only therapy that has, to date, demonstrated efficacy in delaying progression from Stage 2 to Stage 3 T1D. This randomized, double-blind, placebo-controlled trial demonstrated Stage 3 T1D onset was delayed by a median of 2 years in first- or second-degree relatives of individuals with T1D, aged 8–50 years old, with stage 2 T1D at the time of enrollment. Subsequent analysis demonstrated that the median delay might actually have been as long as 3 years in subjects treated with teplizumab versus placebo. Teplizumab is currently being reviewed by the U.S. FDA. If granted approval, teplizumab will become the first immunotherapeutic with such a designation for individuals at risk for T1D. Trials with other drugs targeting autoimmune responses; (2) antigen presentation; (3) glycemic dysregulation; and (4) beta cell stress/dysfunction are also underway.

### Stage 3 T1D Interventions

Stage 3 interventions or “new onset” studies seek to halt the disease, preserve residual β-cell function, and potentially delay or prevent complications of T1D in children and adults with newly diagnosed (6–12 weeks) Stage 3 T1D. Numerous efforts have been made to intervene at this relatively late stage of the disease due to the ease in identifying individuals who might still receive benefit. Ultimately, relatively few agents are considered to have demonstrated capacity to delay C-peptide decline in Stage 3 disease; namely, cyclosporine, teplizumab, abatacept, alefacept, rituximab, golimumab, and low dose anti-thymocyte globulin. However, a growing number of studies continue to focus on Stage 3. These studies not only have the prospect of providing direct benefit to newly diagnosed patients but also provide required safety data, particularly in children, where C-peptide decline is faster than in adults, to support moving therapies into Stage 1 or Stage 2 disease. Ultimately a personalized medicine approach using targeted combination therapies and timing of treatment, driven by the individual patient genetic risk and response biomarkers is likely to be the most effective means of intervening in the disease process.

Clinical trials at Stage 3 of disease have historically not been available in low-income countries. These trials have also enrolled study populations that were predominantly Caucasian, in part due to study sites primarily located in the United States, Canada, United Kingdom, Europe, and Australia. So far, neither efficacy nor risks have been shown to differ by racial/ethnic background in published Stage 3 trials; however, it is possible such differences could be missed due to the preponderance of Caucasian participants. Moreover, there is emerging evidence that GRS does not differ by ethnicity.

### CONCLUSIONS AND RECOMMENDATIONS

Rapid expansion of screening and intervention networks, with the overall aim to prevent progression to Stage 3 diabetes and preserve beta cell function, has occurred in the last 5 years. General population screening for T1D has been propelled by technological advances in the prediction of genetic risk, low volume autoantibody assays, and advancements in trials of interventions to slow the progression of beta cell dysfunction. Screening to detect at-risk children offers the prospect of preventing DKA at presentation, and accelerated discovery of preventative interventions, through enhanced recruitment pools for clinical trials. Screening should therefore be accompanied by clinical care pathways to first reduce risk of DKA, and second, provide the young person or adult with age and stage-appropriate options to receive proven interventions or enter available intervention trials. If effective immunotherapies to delay progression and preserve beta cell function are approved by regulatory bodies, and the cost/benefit ratio related to screening is optimized, it is expected that screening will increasingly become standard practice within the general population. Primary prevention trials in infants and pre-schoolers are planned or

### Table 2 (Continued)

<table>
<thead>
<tr>
<th>Trial</th>
<th>Route</th>
<th>Intervention</th>
<th>Population</th>
<th>Primary outcome</th>
<th>Outcome achieved</th>
</tr>
</thead>
<tbody>
<tr>
<td>TN-08</td>
<td>SC</td>
<td>GAD</td>
<td>Stage 3, new onset, 3–45 y</td>
<td>AUC C-peptide</td>
<td>Unsuccessful</td>
</tr>
<tr>
<td>Diamyd</td>
<td>SC</td>
<td>GAD</td>
<td>Stage 3, new onset, 10–20 y</td>
<td>AUC C-peptide</td>
<td>Unsuccessful</td>
</tr>
<tr>
<td>DIAGNODE-3</td>
<td>IL</td>
<td>GAD</td>
<td>Stage 3, ≤6 m duration, 12–28 y</td>
<td>AUC C-peptide</td>
<td>Ongoing</td>
</tr>
<tr>
<td>Anti-CD40</td>
<td>SC</td>
<td>Iscalimab</td>
<td>Stage 3, new onset, 6–21 y</td>
<td>AUC C-peptide</td>
<td>Ongoing</td>
</tr>
<tr>
<td>BANDIT</td>
<td>PO</td>
<td>Baricitinib</td>
<td>Stage 3, new onset, 10–30 y</td>
<td>AUC C-peptide</td>
<td>Ongoing</td>
</tr>
</tbody>
</table>

Note: Stage 1 = multiple AAb-positive with normal glucose tolerance (via OGTT); Stage 2 = multiple AAb-positive with abnormal glucose tolerance; Stage 3 = clinical diagnosis of T1D. Bolded indicates emphasize those studies that have demonstrated capacity to prevent autoimmunity, delay progression of T1D or preserve beta cell function.

Abbreviations: AAb, autoantibody; FPIR, first-phase insulin response; HLA, human leukocyte antigen; IL, intra-lymphatic; IM, intramuscular; IN, intranasal; IV, intravenous; m, months; PO, per os (oral); SC, subcutaneous; y, years.

*Post hoc subpopulation response.
underway to develop immune tolerance, supplement with probiotics, or vaccinate against putative enterovirus (Coxackie B) genotypes. Ongoing trials at Stages 1, 2, and 3 are evaluating the effects of immune-modulators acting directly and indirectly on T cells and antigen-specific therapies. It is thought that combined therapies will likely be most beneficial. The first therapeutic agent (the anti-CD3 monoclonal antibody, teplizumab) is under consideration by regulatory bodies to delay progression from Stage 2 to 3 T1D. Increasingly therapies will become more individualized to target different mechanisms in the disease pathway, analogous to treatments for other autoimmune diseases such as lupus erythematosus and rheumatoid arthritis.

**AUTHOR CONTRIBUTIONS**

REJB and KJB were co-first authors and reviewed the literature, drafted sections of the guidelines, oversaw completion of the first draft of the guidelines, and edited the manuscript. JJC, AGZ, DKW, MK, CS, KC, KAD, and JL reviewed the literature, provided drafts of sections and edited the manuscript. MEC was the lead of the ISPAD guidelines editorial committee, edited the manuscript, and served as co-senior author. MJH outlined the guidelines, reviewed the literature, drafted sections of the guidelines, edited the manuscript, and served as the corresponding senior author. The authors gratefully acknowledge the editorial assistance of Dr. Leena Priyambada.

**CONFLICT OF INTEREST**

The authors have declared no conflicts of interest.

**PEER REVIEW**

The peer review history for this article is available at https://publons.com/publon/10.1111/pedi.13410.

**DATA AVAILABILITY STATEMENT**

Data sharing not applicable to this article as no datasets were generated or analysed during the current study.

**ORCID**

Jenny J. Couper https://orcid.org/0000-0003-4448-8629
Mikael Knip https://orcid.org/0000-0003-0474-0033
Kristina Castaels https://orcid.org/0000-0001-9690-3551
Kimblyr A. Driscoll https://orcid.org/0000-0002-3006-4633
Laura Jacobsen https://orcid.org/0000-0002-5144-7836
Maria E. Craig https://orcid.org/0000-0001-6004-576X
Michael J. Haller https://orcid.org/0000-0002-2803-1824

**REFERENCES**


49. Greenbaum CJ. A key to T1D prevention: screening and monitoring relatives as part of clinical care. *Diabetes.* 2021;70(5):1029-1037.


in Finland: selective genotyping of markers in the HLA-DQB1, HLA-DQA1 and HLA-DRB1 loci. Diabet Med. 1999;16(12):985-992.


